Alx oncology receives u.s. fda orphan drug designation for evorpacept for the treatment of patients with gastric cancer and gastroesophageal junction cancer

South san francisco, calif., jan. 27, 2022 (globe newswire) -- alx oncology holdings inc., (“alx oncology”) (nasdaq: alxo) a clinical-stage immuno-oncology company developing therapies that block the cd47 checkpoint pathway, today announced that the u.s. food and drug administration (“fda”) granted orphan drug designation (“odd”) to evorpacept, a next-generation cd47 blocker, for the treatment of patients with gastric cancer and gastroesophageal junction cancer (collectively “gc”).
ALXO Ratings Summary
ALXO Quant Ranking